NCT03019003View on ClinicalTrials.gov

Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

March 20, 2017

Primary Completion Date

September 24, 2024

Study Completion Date

September 24, 2024

Conditions
Head and Neck Cancer
Interventions
DRUG

Oral Decitabine

DNA methyltransferase inhibitor

DRUG

Durvalumab

anti-PD-L1

DRUG

5' Azacitidine

DNA methyltransferase inhibitor

DRUG

Tremelimumab

anti-CTLA4

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

Sponsors
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

collaborator

Astex Pharmaceuticals, Inc.

INDUSTRY

lead

Massachusetts General Hospital

OTHER